首页TY - JOUR T1 - Effectiveness of lacosamide monotherapy in clinical practice: a retrospective chart review in patients with focal seizures (P5.230) JF - Neurology JO - Neurology VL - 88 IS - 16 Supplement SP - P5.230 AU - Vincente Villanueva AU - Beatriz Giráldez AU - Manuel Toledo AU - Gerrit-Jan de Haan AU - Eduardo Cumbo AU - Antonio Gambardella AU - Marc De Backer AU - Lars Joeres AU - Marcus Brunnert AU - Peter Dedeken AU - Jose Serratosa Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P5.230.abstract N2 - Objective: To assess effectiveness and tolerability of lacosamide monotherapy in patients with focal seizures (FS).Background: Lacosamide is approved as monotherapy for FS in the USA!缺日临床实践发布数据.设计/方法:回溯评估欧洲16岁观察点12/3月结果包括业务方案3保留率(12+3个月)、业务方案2收缴自由率(6+3个月)和业务方案3和治疗突发不良药反应(TEADRs)。++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++一线保留率和转换为单治子类为60.2%(59/98!95%置信区间50.5%-69.9%,62.5%3-67.6%)卡普兰-梅耶估计12个月的保留率分别为81.2%和91.4%第一线和转入单疗法++65岁病人保留率分别为6.0%(40.8-79.2%)和68.9%(6.0-77.9%)第一行转换为单治实验2中66.3%第一行和63.0%转为单治病人免费(odds-ratio 1.15[95%CI 0.713-1.839])。OP3中60.2%第一线和52.5%转换为单治病人免费(odds-ratio 1.80[95%CI1.080-3.001])。65岁病人2单行和转单治分别占72.0%和68.0%,3例68.0%和56.3%。整体而言,2/439(11.8%)病人报告TEADRs(16.4%为#65岁病人),最常见的(%1%)头晕(5.0%)、头痛(2.1%)和求同存异(1.6%)。Villanueva因Eisai、UCB、Bial、Novartis和Esteve参加咨询局或行业赞助的研讨会而获得个人补偿Giraldez博士因与UCBPharma通话活动而获得个人补偿博士托莱多因UCB Pharma、BIAL、EISAI、Esteve和Shire咨询公司的活动而获得个人补偿博士托莱多得到了EISAI和BIAL的研究支持博士de Haan个人因UCBPharma担任演讲人和/或咨询人而获得补偿博士Cumbo没什么可透露博士Gambardella因咨询、科学咨询委服务或科学会议讲演EISA博士和UCBDe Backer因UCBPharma雇员活动而获得个人补偿博士Joeres因UCBPharma活动获得个人补偿博士Brunnert因UCB生物科学GmbH雇员活动而获得个人补偿博士Deken因UCBPharma雇员活动而获得个人补偿塞拉托萨博士因与UCB、Esteve、EisaiLtd、Bial和CebronicsER-